The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II randomized trial on dose-escalated sorafenib (S) versus best supportive care (BSC) in patients with advanced hepatocellular carcinoma (HCC) with disease progression on prior S treatment.
T. Pressiani
No relevant relationships to disclose
L. Rimassa
No relevant relationships to disclose
C. Boni
No relevant relationships to disclose
R. Labianca
No relevant relationships to disclose
S. Fagiuoli
No relevant relationships to disclose
A. Ardizzoni
No relevant relationships to disclose
P. Foa
No relevant relationships to disclose
E. Cortesi
No relevant relationships to disclose
C. Porta
No relevant relationships to disclose
F. Artioli
No relevant relationships to disclose
L. Latini
No relevant relationships to disclose
C. Carnaghi
No relevant relationships to disclose
R. F. Lutman
No relevant relationships to disclose
G. Torzilli
No relevant relationships to disclose
M. Tommasini
No relevant relationships to disclose
R. Ceriani
No relevant relationships to disclose
G. Covini
No relevant relationships to disclose
L. Giordano
No relevant relationships to disclose
N. Locopo
No relevant relationships to disclose
A. Santoro
No relevant relationships to disclose